GTHX Oct 2024 2.500 put
| Previous close | 0.8500 |
| Open | 0.8500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.50 |
| Expiry date | 2024-10-18 |
| Day's range | 0.8500 - 0.8500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireMeaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data for the ADC Alone - - Exploratory Analysis of a More Comparable Patient Population Showed an Approximately Six-Month Improvement in Median OS Among Patients Receiving Trilaciclib in Combination with the ADC Compared to Historical ADC Data - - Prolonged OS Observed in Patients Recei
- GlobeNewswire
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjugate (ADC) sacituzumab govitecan (SG) on overall survival (OS) and tolerability compared to SG alone based on historical data from the ASCENT trial will be presented in a poster session during the upcoming 2024
- GlobeNewswire
G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit
RESEARCH TRIANGLE PARK, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Medical Officer Dr. Raj Malik and Chief Commercial Officer Andrew Perry will participate in a fireside chat at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, on Wednesday, May 29, at 8:30AM EDT. The webcast of the event will be accessible on the Events & Presentations page of http://www.g1therapeutics
